权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Center for Mucosal Immunobiology and Rheumatic Disease Pathogenesis

粘膜免疫生物学和风湿病发病机制中心

基本信息

批准号：
10277290
负责人：
Vernon Michael Holers
金额：
$ 77.75万
依托单位：
UNIVERSITY OF COLORADO DENVER
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-09-10 至 2026-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10277290
关键词：
Attention Autoantigens Autoimmune Diseases Autoimmunity Biological Markers Blood specimen CLIA certified Cell Communication Cells Chronic Clinical Collaborations Colorado Communication Computer Analysis Consultations Data Data Analyses Data Science Data Science Core Data Set Development Diagnostic Direct Costs Disease Education Environment Epidemiology Epithelial Evolution Funding Future Goals Grant Grant Review Healthcare Systems Human Immunobiology Immunologic Markers Immunologic Techniques Immunology Individual Inflammation Inflammatory Infrastructure Investments Letters Medicine Mesenchymal Methodology Methods Mission Molecular Mucosal Immune Responses Mucosal Immune System Mucous Membrane NCI Scholars Program Newsletter Online Systems Outcome Participant Pathogenesis Pathway interactions Patient Care Patients Peripheral Phase Phenotype Play Population Population Sciences Population Study Populations at Risk Process Program Development Research Research Personnel Resources Rheumatism Rheumatoid Arthritis Role Sampling Sampling Studies Science Series Services Source Spondylarthropathies Study Subject Systemic Lupus Erythematosus Technology Technology Assessment Testing Therapeutic Tissue Sample Tissues Training Translating Translations Universities base biobank biomarker development career clinical care cohort commercialization complex data data management design direct patient care discount dysbiosis early detection biomarkers human disease improved improved outcome innovation insight interest member metabolome metabolomics microbial microbiome microbiome analysis mid-career faculty mucosal site novel novel marker novel strategies novel therapeutics outreach peripheral blood personalized medicine pre-clinical prevent professor programs ranpirnase recruit research and development single cell technology skills social media symposium systemic autoimmunity systemic inflammatory response therapy development

项目摘要

A substantial cadre of investigators at the University of Colorado are focused on characterizing the molecular origins and causal mechanisms that drive the initiation and preclinical phases of rheumatic and autoimmune diseases. One of the most important outcomes of those efforts has been the demonstration in populations at- risk for future disease that dysbiosis and chronic inflammation at mucosal sites can promote the initial local development of disease-specific loss of tolerance to autoantigens. Ultimately, this process leads to systemic autoimmunity and the development of diseases including rheumatoid arthritis (RA) and spondyloarthroarthritis (SpA). Building on that concept with unique at-risk populations and an extensive programmatic infrastructure, a P30 Rheumatic Disease Research Resource Center (RDRRC) entitled “Center for Mucosal Immunobiology and Rheumatic Disease Pathogenesis” is proposed. Included in the Center are an Administrative Core, a Population and Data Sciences Core, and a Mucosal Immunobiology Core. This Center is specifically designed to facilitate studies of human disease pathogenesis that incorporate the broad range of mucosal and systemic immunologic techniques, as well as develop new approaches, to study these integrated mechanisms in already recruited cohorts of individuals throughout the preclinical and then clinically active phases of disease. The Center includes 43 internal and external members who have in aggregate $77M in related annual direct cost grant funding. In addition to providing access to stored biospecimens and data from ongoing population studies, the Center will provide consultative and member discount mechanisms for all of the critical aspects of cohort development, epidemiologic assessment, data management and data analyses. In addition, the Center will provide members access to technologies that focus on analyses of the microbiome and microbial:cell interactions, as well as informative mucosal and peripheral immune biomarkers. The Center will build on a recent $80M investment from the Dean to fund four other relevant programs with which this Center will interact. Dr. Michael Holers, Professor of Medicine and Immunology, will serve as the Center Director, and Dr. Kristi Kuhn, Associate Professor of Medicine, will serve as the Associate Director. Both will interact with Advisory and Executive Committees, and in the latter will be joined by Core Directors and Co-Directors with domain expertise. As a key component of the mission of the Center, a Pilot & Feasibility Grants Program will be developed with substantial institutional support. Additional Enrichment Program activities will include a seminar series, technology assessment series, and an annual symposium. A major focus will be on early career investigator development through enhanced Core access as well as Grants Review and a Scholars Programs. Social media, web-based outreach and newsletters will provide comprehensive communication. Finally, a Patient Impact Program will be utilized for the assessment and enhanced translation of novel biomarkers and therapeutically relevant RDRRC discoveries into direct patient care with the goal to improve outcomes.

科罗拉多大学（University of Colorado）的一大批研究人员正专注于描述这种分子的特征